Mycophenolate mofetil in pancreas transplantation

Transplantation

Volumn 66, Issue 3, 1998, Pages 318-323

  Gruessner, Rainer W G ^a,b   Sutherland, David E R ^b   Drangstveit, Mary Beth ^b   Wrenshall, Lucile ^b   Humar, Abhinav ^b   Gruessner, Angelika C ^b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ARTICLE; BONE MARROW TOXICITY; FEMALE; GASTROINTESTINAL TOXICITY; GRAFT REJECTION; GRAFT SURVIVAL; HLA SYSTEM; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 0032529430     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199808150-00007     Document Type: Article

References (15)

1. Gruessner AC, Sutherland DER. Pancreas transplants for United States (U.S.) and non-U.S. cases as reported to the International Pancreas Transplant Registry (IPTR) and to the United Network for Organ Sharing (UNOS). In: Cecka JM, Terasaki PI, eds. Clinical transplants 1997. Los Angeles, CA: UCLA Tissue Typing Laboratory, 1998: 45.
2. Lee WA, Gu L, Miksztal AR, Chu N, Leung K, Nelson PH. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res 1990; 7: 161.
3. Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 1993; 136: 1.
4. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321.
5. Sollinger HW for the U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225.
6. Tricontinental Mycophenolate Mofetil Renal Transplant Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029.
7. Halloran P for the International Mycophenolate Mofetil Renal Transplant Study Groups. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. Transplantation 1997; 63: 39.
8. Stratta RJ. Simultaneous use of tacrolimus and mycophenolate mofetil in combined pancreas/kidney transplant recipients: a multicenter report. Transplant Proc 1997; 29: 654.
9. Morel P, Goetz FC, Moudry-Munns K, Freier E, Sutherland DER. Long-term glucose control in patients with pancreatic transplants. Ann Intern Med 1991; 115: 694.
10. Gruessner RWG. Tacrolimus in pancreas transplantation: a multicenter analysis. Clin Transplant 1997; 11: 299.
11. Gruessner RWG, Sutherland DER, Drangstveit MB, Troppmann C, Gruessner AC. Use of FK506 in pancreas transplantation. Transplant Int 1996; 9: S251.
12. Gruessner RWG. Antibody induction therapy in pancreas transplantation: pro. Transplant Proc 1998; 30: 1556.
13. Gruessner RWG, Sutherland DER, Najarian JS, Dunn DL, Gruessner AC. Solitary pancreas transplantation for nonuremic patients with labile insulin-dependent diabetes mellitus. Transplantation 1997; 64: 1572.
14. Stegall MD, Simon M, Wachs ME, Chan L, Nolan C, Kam I. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine. Transplantation 1997; 64: 1695.
15. Gruessner RWG, Sutherland DER, Drangstveit MB, West M, Gruessner AC. Mycophenolate mofetil and tacrolimus for induction and maintenance therapy after pancreas transplantation. Transplant Proc 1998; 30: 518.